The Monoclonal Antibody Core Facility (MACF) facilitates the acquisition and development of new antibodies for research studies by investigators in the Cancer Center. In some cases, antibodies are prepared in quantities and with purity suitable for in vivo preclinical studies. As such the MSCF is a vibrant and innovative core that contributes broadly to the basic and translational mission of the Center. Specifically the Core develops new MAbs/ hybridomas to a specific antigen of interest that work in the required application. The facility provides access to MAbs not otherwise readily available by: 1) Producing MAbs (in vitro);2) Purifying MAbs;3) Conjugating MAbs to fluorphores, proteins, Q dots;3) Fragmenting MAbs into Fab and/or F(Ab')2 fragments. Cell cultures are a staple in cancer research and healthy cells are essential to acquiring solid and reproducable data from these in vitro systems. Since mycoplasmal contamination significantly alters cellular processes, routine testing is a good laboratory practice. To minimize problems from such contaminations the MACF also offers a mycoplasma testing service. The services provided by the Monoclonal Antibody Core have supported the research of 78 investigators in the past year. During the past grant period the work of the Core has contributed to 149 publications of researchers from 6 research programs, A recent paper from the laboratory Hans-Guido Wendel illustrates how the facility also meets novel requests. Wendel's work demonstrated that soluble Eph-receptor A7 suppresses tumor growth. This classification as a tumor suppressor is further supported by the fact that it Is lost in ~ 70% follicular lymphomas. The MACF contributed by purifying an anti-CD20-EPHA7 recombinant fusion antibody the Wendel group produced which had a therapeutic effect In tumor bearing mice. This customized chimeric protein was more effective than the parental CD20 antibody (Rituximab) at shrinking large tumors.

Public Health Relevance

The MACF provides a comprehensive suite of services that enable antibody design, production, and use for basic research and for in vivo preclinical studies. Monoclonal antibodies are central reagents in the toolbox of not only basic and clinical researchers, but also in the clinic where they are utilized in the diagnosis and treatment of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-48
Application #
8933518
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2014-01-01
Project End
2018-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
48
Fiscal Year
2014
Total Cost
$282,755
Indirect Cost
$123,636
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Gounder, Mrinal M; Solit, David B; Tap, William D (2018) Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation. N Engl J Med 378:1945-1947
Mendonca, Shawn J; Sanchez, Alejandro; Blum, Kyle A et al. (2018) The association of renal cell carcinoma with gastrointestinal stromal tumors. J Surg Oncol 117:1716-1720
O'Cearbhaill, Roisin E (2018) Using PARP Inhibitors in Advanced Ovarian Cancer. Oncology (Williston Park) 32:339-43
Lichtenthal, Wendy G; Maciejewski, Paul K; Craig Demirjian, Caraline et al. (2018) Evidence of the clinical utility of a prolonged grief disorder diagnosis. World Psychiatry 17:364-365
Cottrell, T R; Thompson, E D; Forde, P M et al. (2018) Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC). Ann Oncol 29:1853-1860
Pereira, PatrĂ­cia M R; Sharma, Sai Kiran; Carter, Lukas M et al. (2018) Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. Nat Commun 9:5137
Mano, Roy; Di Natale, Renzo; Sheinfeld, Joel (2018) Current controversies on the role of retroperitoneal lymphadenectomy for testicular cancer. Urol Oncol :
Zhu, Guo; Benayed, Ryma; Ho, Caleb et al. (2018) Diagnosis of known sarcoma fusions and novel fusion partners by targeted RNA sequencing with identification of a recurrent ACTB-FOSB fusion in pseudomyogenic hemangioendothelioma. Mod Pathol :
Gollub, Marc J; Hotker, Andreas M; Woo, Kaitlin M et al. (2018) Quantitating whole lesion tumor biology in rectal cancer MRI: taking a lesson from FDG-PET tumor metrics. Abdom Radiol (NY) 43:1575-1582
Rapp, Moritz; Wiedemann, Gabriela M; Sun, Joseph C (2018) Memory responses of innate lymphocytes and parallels with T cells. Semin Immunopathol 40:343-355

Showing the most recent 10 out of 8799 publications